Since Johnson & Johnson announced plans to cease supply of the Linx device to the European market in 2026, a group of UK surgeons have appealed to the company to support on-going supply to the UK. This was never a decision based on clinical outcomes, which many of us have found to be extremely positive, but an entirely commercial one from J&J.
To their credit, the company have actively listened and engaged with us and a regulatory approval from MHRA has now been granted. This means that the Linx device will continue to be available to patients in the UK.